Lansdowne Partners
VC Fund
London, United Kingdom
Lansdowne Partners is an alternative investment management firm that focused on equity portfolios. Founded in 1998, the company manages assets for a diversified institutional client base that includes some of the world’s largest and most sophisticated investors. Lansdowne Partners was founded in 1998 and is based in London, England.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 20%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Lansdowne Partners invests in
Stages Lansdowne Partners invests in
Countries Lansdowne Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $6.7M–$55M
- Series B
- $8.5M–$100M
Investment Focus
Industry
- Biotechnology 9 (20%)
- Finance 3 (7%)
- Genetics 3 (7%)
- Health Care 3 (7%)
- Machine Learning 3 (7%)
Stage
- Funding Round 10 (22%)
- Series A 8 (18%)
- Series B 7 (16%)
- Series C 6 (13%)
- Seed 3 (7%)
Country
- United Kingdom 20 (44%)
- Austria 3 (7%)
- United States 2 (4%)
- Malta 1 (2%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Ryder
Chief Risk Officer
|
Chief Risk Officer | Total investments: 0 | Find email | |
|
Hugh Orange
Partner, Chief Compliance Officer & Chief Financial Officer
|
Partner, Chief Compliance Officer & Chief Financial Officer | Total investments: 0 | Find email | |
|
Paul Ruddock
Co-Founder and CEO
|
Co-Founder and CEO | Total investments: 0 | Find email | |
Suzi Nutton
Partner & Chief Executive Officer
|
Partner & Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MoA Technology
|
MoA Technology Limited is a plant genetics company spun out from the University of Oxford. Professor Liam Dolan, FRS, has developed an innovative approach for the discovery of agricultural technologies that will enable farmers to produce healthy food from sustainable crop systems. | $29.7M / Series C / Jul 23, 2026 | |
amnis
|
The simplest, fastest, and most affordable international payment platform for SMEs | $11.2M / Series B / Feb 26, 2025 | |
Nattergal
|
Nattergal operates as a nature restoration company. | $52M / Seed / Oct 16, 2024 | |
G.ST Antivirals
|
G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply. | $6.7M / Series A / Jan 25, 2024 | |
Oxford Quantum Circuits
|
Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies. | $100M / Series B / Nov 27, 2023 | |
TechMet
|
TechMet is a private industrial company that is building projects to secure the supply of the key metals critical to the future growth of EVs, Energy Storage and Renewable Energy. TechMet currently holds interests in both production and development assets in Africa, North America, and South America. | Aug 15, 2023 | |
|
TechMet
|
TechMet is a private industrial company that is building projects to secure the supply of the key metals critical to the future growth of EVs, Energy Storage and Renewable Energy. TechMet currently holds interests in both production and development assets in Africa, North America, and South America. | $200M / Aug 15, 2023 | |
Tungsten West
|
Tungsten West plc producing hemerdon mine. With demand for strategic metals, including tungsten and tin increasing rapidly, due to their heavy use in new technology, Tungsten West is concentrated on meeting this demand by restarting production at Hemerdon in the next 12 months at a low cost due to existing infrastructure. | $8.7M / Post-IPO Debt / May 19, 2023 | |
Oxford Ionics
|
Oxford Ionics is a quantum computing startup that provides innovations for the development of accurate and dependable quantum computers by combining high-performance qubits - trapped ions - with a noiseless electronic qubit control technology. Oxford Ionics' technology enables the manipulation of qubits with negligible noise and reliability,giving clients access to quantum computers that can control interconnected qubit registers in parallel and without sacrificing performance. | $36.6M / Series A / Jan 09, 2023 | |
Osler Diagnostics
|
Osler is a UK-based diagnostics company whose purpose is to enable anyone, anywhere, to access, understand, and act on their health, to live healthier, happier, and longer lives.Osler has developed the Osler Origin – a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin will offera wide portfolio of diagnostic tests and serve all major healthcare settings, globally. Osler was formed out of the University of Oxford in 2017, following decades of research from the same department that invented the portable electrochemical blood glucose sensor. The Company is headquartered in Oxford, UK. | $85M / Series C / Nov 07, 2022 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lansdowne Partners invest in?
Lansdowne Partners invests primarily in Biotechnology, Finance and Genetics startups, most often at Funding Round and Series A stage. Most of the 45 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Lansdowne Partners's check size?
Lansdowne Partners typically joins rounds of $6.7M–$55M at Series A and $8.5M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lansdowne Partners participates in.
How do I contact Lansdowne Partners?
Public channels for Lansdowne Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lansdowne Partners?
The team at Lansdowne Partners includes Andrew Ryder (Chief Risk Officer), Hugh Orange (Partner, Chief Compliance Officer & Chief Financial Officer) and Paul Ruddock (Co-Founder and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
